A previous study reported that ferroptosis regulators like GPX4 are associated with tumor progression and tumor sensitivity to treatments, such as hepatocellular carcinoma, renal cell carcinoma, breast cancer, prostate cancer, and bladder carcinoma (6–8). The gene discussed is GPX4; the disease is neoplasm.